The FDA ANDA review nearing completion with only a vial attestation remaining is the most near-term catalyst, approval and commercial launch could transform the company from pre-revenue to revenue-generating. Monitor for FDA decision on the ANDA and any updates on the DARPA contract finalization, as these represent the primary value drivers over the next 3-6 months.
Drug in focus
NRXP drug pipeline →Preservative-Free Ketamine
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Next catalyst
- None dated
What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.43entry
- T+1 · 3mo ago +0.29%α +0.97% · $3.44
- T+5 · 3mo ago +0.58%α +1.77% · $3.45
- T+20 · 2mo ago +1.75%α +3.28% · $3.49
- T+60 · 7d ago −30.61%α −27.85% · $2.38
Price Chart
How similar events traded
Executive Summary
NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months ended June 30, 2026, compared to a $23.1M loss in the prior-year period. The company highlighted key regulatory progress on its ANDA for preservative-free ketamine, a DARPA contract for NRX-101, and a strengthened cash position of $26.7M following a $22.3M public offering, extending its cash runway to at least one year. The filing is bullish due to the tangible regulatory and funding milestones, though the company remains pre-revenue with operating losses widening.
Key Facts
- Completed first-cycle FDA review of ANDA for preservative-free ketamine with no drug-related major deficiencies; sole remaining item (manufacturer's attestation) submitted.
- Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; anticipated non-dilutive funding exceeds $11.5 million.
- Closed institutionally-supported underwritten public offering for gross proceeds of $22.3 million, including full exercise of underwriters' option.
- Cash and cash equivalents of $26.7 million as of June 30, 2026, up from $7.8 million at December 31, 2025.
- Net loss for six months ended June 30, 2026 was $18.0 million vs $23.1 million in prior-year period; net operating loss was $11.3 million vs $7.6 million.
- Appointed Glenn Tyson as first Chief Commercial Officer and retained commercial launch team for preservative-free ketamine.
- HOPE Therapeutics expanded clinical footprint with new sites in Florida and became first US commercial site to use Zeta Surgical's FDA-cleared TMS navigation system.
Financial Impact
Cash balance increased by $18.9M from year-end 2025 to $26.7M; net loss improved by $5.1M vs prior-year six-month period; operating loss widened by $3.7M due to R&D and commercial launch costs.
Risk Factors
- ANDA approval is not guaranteed; FDA could still issue additional deficiencies or reject the application.
- Company remains pre-revenue with widening operating losses; cash runway depends on successful commercialization and potential further dilution via the at-the-market offering facility.
- DARPA funding is subject to completion of contracting and may not materialize as anticipated.
- NRX-100 NDA and NRX-101 Phase 2/3 trial are years away from potential approval; clinical failure risk is significant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-028111 |
| Exhibit: ex_1005774.htm | 0001437749-26-028111 |
| Document: 0001437749-26-028111-index-headers.html | 0001437749-26-028111 |
| Document: 0001437749-26-028111-index.html | 0001437749-26-028111 |
| Document: 0001437749-26-028111.txt | 0001437749-26-028111 |
| 8-K Data (Synthetic) | 0001437749-26-028111 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Viewing Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers